Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic immunotherapy, and personalized mesenchymal stem cells (pMSCs) from its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results